section
Navigation Links
section at medicine technology
Choosing Lab Quality Management Software
...ditation. Other team members, who hailed from each section of the multi-disciplinary lab, also devoted many hours to accreditation management. These hours included time spent on meetings and other communications within the accreditation team, finding and organizing the supporting evidence for each checklist...Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
...and its business can be foundin the "Risk Factors" section of its Form 20F for the year endedMay 31, 2006. For more information, please contact: Derek Reimer Adam Peeler Chief Financial Officer Manager of Investor & PublicRelations Tel. 888-435-2220 Fax 204-488-9823 E-mail: <a target="_blan...Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
...io webcast please visit the "Investors &Media" section of the company's website located at <a target="_blank" href="http://www.manhattanpharma.com/">http://www.manhattanpharma.com .An archived webcast will be available on the website approximately2 hours after the event and will be available in t...ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
...ation will be available onthe Investor Information section of the ViaCell website athttp://www.viacellinc.com. A replay of the presentation will beavailable for approximately three months after the webcast. About ViaCell ViaCell, Inc. is a biotechnology company dedicated to enablingthe widespread applicatio...Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
...ast can be accessed through the Investor Relations section ofAccelrys' web site at www.accelrys.com or by visiting the followingweb address: http://www.wsw.com/webcast/ceut6/accl/. To learn more about C.E. Unterberg, Towbin, please visitwww.unterberg.com. About Accelrys, Inc. Accelrys develops and commerc...Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
...Calendar of Events" page in theInvestors and Media section of the Sunesis website for two weeksuntil July 26, 2007. Option Award Disclosure The Compensation Committee of the company's Board of Directorsapproved an employment commencement grant to Mr. Michael Coors,Director, Quality Assurance, of a non-qual...Tercica to Present at Investment Conferences
...vailablevia the Internet by visiting the Investors section of the Company'sWeb site at www.tercica.com. An archived presentation will beavailable on the Web site for 21 days. Tercica also announced management's participation in the PacificGrowth Equities One on One Session: Focus on Cardiology andMetabolic ......e presentation will be available onthe "Investors" section of the company's website, <a target="_blank" href="http://www.rosettagenomics.com/">www.RosettaGenomics.com . Areplay of the presentation will be available for 30 days after theconference. About Rosetta Genomics Rosetta Genomics is a leader...SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
...ntation will be available on theInvestor Relations section of the Company's Web site at <a target="_blank" href="http://www.supergen.com/">http://www.supergen.com . The webcastwill be archived for 90 days. About SuperGen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceuticalcompany dedicated t...ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
... can be accessed byvisiting the Investor Relations section at www.ziopharm.com. Thewebcast will be archived for ninety days. About ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc. applies new insights from molecular andcancer biology to understand the efficacy and safety limitations ofapproved and developme...Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
...ble through a link posted onthe investor relations section of the Icagen website atwww.icagen.com. The webcast will also be available for replay onthe website for at least two weeks following the presentation. About Icagen Icagen, Inc. is a biopharmaceutical company based in ResearchTriangle Park, North Ca......is of Financial Condition andResults of Operations section of the Genzyme Quarterly Report onForm 10-Q for the quarter ending March 31, 2007. Genzyme cautionsinvestors not to place substantial reliance on the forward- lookingstatements contained in this press release. These statements speakonly as of the dat...Avexa's Apricitabine Clinical Trial Update
...l.Patients have now progressed into the open-label section of thetrial (weeks 24 to 48) and will continue to receive 800mgapricitabine twice a day as part of their daily treatment regime.The Company expects to release results from the 24 week blindedphase later this quarter. Avexa also reported that apricita...Genzyme Announces Results of Clinical Trial of Hylastan
...isof Financial Condition and Results of Operations section of theGenzyme Quarterly Report on Form 10-Q for the quarter ending March31, 2007. Genzyme cautions investors not to place substantialreliance on the forward-looking statements contained in this pressrelease. These statements speak only as of the date......r theInternet. Please visit the Investor Relations section of theAdvanced Life Sciences corporate website <a target="_blank" href="http://www.advancedlifesciences.com/">www.advancedlifesciences.com .Alternatively, callers may participate in the conference call bydialing 800-561-2601(domestic) or 617-......r theInternet. Please visit the Investor Relations section of theAdvanced Life Sciences corporate website <a target="_blank" href="http://www.advancedlifesciences.com/">http://www.advancedlifesciences.com .Alternatively, callers may participate in the conference call bydialing 800-561-2601(domestic) ......his press release is also available under theMedia section of the Company's website at: <a target="_blank" href="http://www.millennium.com/">www.millennium.com . Contacts: Jennifer Snyder (media) Kyle Kuvalanka (investors) (617) 444-1439 (857) 498-0818 CONTACT: Media, Jennifer Sny......his press release is also available under theMedia section of the Company's website at: <a target="_blank" href="http://www.millennium.com/">www.millennium.com . Contacts: Jennifer Snyder(media) KyleKuvalanka (investors) (617)444-1439 (857) 498-0818 SO...CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
...other risks that can be found in the"Risk Factors" section of the CombinatoRx Annual Report on Form10-K on file with the Securities and Exchange Commission and theother reports that CombinatoRx periodically files with theSecurities and Exchange Commission. Actual results may differmaterially from those Combi...... the "Webcastsand Events" link under the Investors section of Aspreva's website.A replay of the webcast will ...ted withAspreva's business, see the "Risk Factors" section in Aspreva'sQuarterly Report on Form 10-Q for the quarter ended March 31, 2007,filed with the U.S. S......webcast will be available in theInvestor Relations section of www.neurogen.com and will also bearchived there. A replay of the call will be available after 1:00pm ET today and accessible through the close of business, July 9,2007. To replay the conference call, dial 888-286-8010, or forinternational callers,......ally frommanagement's expectations is found in the section entitled "RiskFactors" in the Company's 2006 Annual Report on Form 10-KSB.Although the Company believes these assumptions are reasonable, noassurance can be given that they will prove correct. Accordingly,you should not rely upon forward-looking stat...Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
... be found at www.nejm.org under the"Current Issue" section of the Web site. The researchers conducted a randomized, controlled, phase 3study comparing Paromomycin, an aminoglycoside, and amphotericin B,the present standard of care in Bihar, India. Paromomycin was shownto be noninferior to amphotericin B wit...Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
...o the call live over the Internet fromthe investor section of the company's Web site or by dialing thenumbers listed below. A detailed PowerPoint presentation willaccompany the webcast. Conference Call Details: Dial-In: (800) 291-5365 (U.S.) (617) 614-3922 (Internation......year ended December31, 2006 and the "Risk Factors" section of Anadys' Form 10-Q forthe quarter ended March 31, 2007. All forward-looking statementsare qualified in their entirety by this cautionary statement.Anadys is providing this information as of this date and does notundertake any obligation to update a......available from the homepage and theinvestors/media section of the Company's web site at <a target="_blank...oking statementsis contained in the "Risk Factors" section of the Company's AnnualReport on Form 10-K for the year ended December 31, 2006, and inthe Company's......his press release is also available under theMedia section of the Company's website at: <a target="_blank" href="http://www.millennium.com/">www.millennium.com . All sessiontimes listed are Eastern European Daylight Time. CONTACT: Jennifer Snyder (media), +1-617-444-1439, or KyleKuvalanka(investors)...Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
...isof Financial Condition and Results of Operations section inGenzyme’s Quarterly Report on Form 10-Q for the period endedMarch 31, 2007. Genzyme cautions investors not to place substantialreliance on the forward-looking statements contained in this pressrelease. These statements speak only as of the da...Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
...is of Financial Condition andResults of Operations section in Genzyme's Quarterly Report on Form10-Q for the period ended March 31, 2007. Genzyme cautionsinvestors not to place substantial reliance on the forward-lookingstatements contained in this press release. These statements speakonly as of the date of ......Company's filings. We refer youto the Risk Factors section of the Company's Management'sDiscussion & Analysis of Financial Condition and Results ofOperations which contain a more exhaustive analysis of the risksand uncertainties that are generally connected to the business ofthe Company. Such statements ...Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
...sare available in the "Events & Presentations" section ofPharmasset's website at <a target="_blank" href="http://www.pharmasset.com/">http://www.pharmasset.com . An in vitro study of Clevudine, expected to enter Phase 3registration clinical trials for the treatment of hepatitis B virus(HBV), dem...Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
...er factors that are described in the"Risk Factors" section (Part II, Item 1A) of Vanda's report on Form10-Q for the quarter ended March 31, 2007 (File No. 000-51863). Noforward-looking statements can be guaranteed and actual results maydiffer materially from such statements. The information in thisrelease is...Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
...ther risks that can be found in the "Risk Factors" section of theCombinatoRx Annual Report on Form 10-K on file with the Securitiesand Exchange Commission and the other reports that CombinatoRxperiodically files with the Securities and Exchange Commission.Actual results may differ materially from those Combi......lving HGS products may inquirevia the "Contact Us" section of the Company's Web site, <a target="_blank" href="http://www.hgsi.com/products/request.html">www.hgsi.com/products/request.html ,or by calling (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, Albuferon, BLyS andLymphoSt...... described in greater detail in the "Risk Factors" section ofour most recent Quarterly Report on Form 10-Q and other filingsthat we make with the Securities and Exchange Commission. If one ormore of these factors materialize, or if any underlying assumptionsprove incorrect, our actual results, performance or...CuraGen Presents Update on Clinical Development Program for Belinostat
...th the Securities and ExchangeCommission under the section "Risk Factors," as well as otherdocuments that may be filed by CuraGen from time to time with theSecurities and Exchange Commission. As a result of such risks,uncertainties and factors, the Company's actual results may differmaterially from any futur......revoke the registration ofIMPAX's securities under section 12 of the Securities Exchange Act,IMPAX's delay in filing its periodic reports subsequent to its Form10-Q for the third quarter of 2004, IMPAX's ability to obtainsufficient capital to fund its operations, the difficulty ofpredicting FDA filings and a......ther risks that can be found in the "Risk Factors" section of theCombinatoRx Annual Report on Form 10-K on file with the Securitiesand Exchange Commission and the other reports that CombinatoRxperiodically files with the Securities and Exchange Commission.Actual results may differ materially from those Combi...Prana Biotechnology Presents New Key Findings on PBT2
... "forward-looking statements" withinthe meaning of section 27A of the Securities Act of 1933 andsection 21E of the Securities Exchange Act of 1934. The Company hastried to identify such forward-looking statements by use of suchwords as "expects," "intends," "hopes," "anticipates," "believes,""could," "may," ...Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
...volving HGS products may inquire via theContact Us section of the Company's web site, <a target="_blank"href="http://www.hgsi.com/products/request.html">www.hgsi.com/products/request.html ,or by calling us at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoSt...Indevus Reports Positive Data From Phase III NEBIDO Trial
...ebcast will be accessible byvisiting the Investors section of the Company's website, <a target="_blank" href="http://www.indevus.com/">http://www.indevus.com .An archived version of the call will be accessible at the same webaddress for 30 days following the live call. About NEBIDO NEBIDO(R) is a l...Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
...ormat can be viewed and/ordownloaded from the News section of the Company's website,<a target="_blank" href="http://www.santaris.com/">www.santaris.com . The Clinical Trial reported here was an open-label,international, multi-centre, dose-escalating study in 25 patientswith relapsed or refractory Ch......; and other factors discussed inthe "Risk Factors" section of Metabasis' Quarterly Report on Form10-Q for the year ended March 31, 2007. All forward-lookingstatements are qualified in their entirety by this cautionarystatement. Metabasis is providing this information as of the dateof this release and does no...Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
...t can be accessed by logging on to the "Investors" section ofSynta Pharmaceuticals' website, www.syntapharma.com, prior to theevent. The call also can be accessed by dialing (877) 407-8035 or (201)689-8035 prior to the start of the call. Following the call, thewebcast will be archived on the Company's websi...Synta Pharmaceuticals to Host Conference Call Today
...t can be accessed by logging on to the "Investors" section ofSynta Pharmaceuticals' website, www.syntapharma.com, prior to theevent. The call also can be accessed by dialing (877) 407-8035 or (201)689-8035 prior to the start of the call. The webcast will bearchived on the Company's website. About Synta Pha...Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
...actices. For moreinformation, visit the "Research" section under "Our Services" onthe company's Web site, <a target="_blank" href="http://www.usoncology.com/">www.usoncology.com . About US Oncology, Inc. US Oncology, headquartered in Houston, is one of the nation'slargest cancer treatment and resea......actices. For moreinformation, visit the "Research" section under "Our Services" onthe company's Web site, <a target="_blank" href="http://www.usoncology.com/">http://www.usoncology.com . About US Oncology, Inc. US Oncology, headquartered in Houston, is one of the nation'slargest cancer treatment an...Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO
... this Phase 2 trial, visit theRecent Presentations section of the Company's web site at<a target="_blank" href="http://www.entremed.com/">www.entremed.com . Temodar(R) is aregistered trademark of its owner and Panzem(R) is a registeredtrademark of EntreMed, Inc. About EntreMed EntreMed, Inc. is a c......and its business can be found inthe "Risk Factors" section of Pharmion's Quarterly Report on Form10-Q for the quarterly period ended March 31, 2007, its AnnualReport on Form 10-K for the year ended December 31, 2006 and inPharmion's other filings with the U.S. Securities and ExchangeCommission. Forward-looki......and its business can be found in the "RiskFactors" section of Pharmion's Quarterly Report on Form 10-Q forthe quarterly period ended March 31, 2007, its Annual Report onForm 10-K for the year ended December 31, 2006 and in Pharmion'sother filings with the U.S. Securities and Exchange Commission.Forward-looki......62;http://www.zymogenetics.com inthe "What's New" section on the home page. About Atacicept ZymoGenetics and Merck Serono, an affiliate of Merck KGaA,Darmstadt, Germany, are developing atacicept (formerly referred toas TACI-Ig) for the treatment of autoimmune diseases and B-cellmalignancies. Atacicept con......and its business can be found in the "RiskFactors" section of Pharmion's Quarterly Report on Form 10-Q forthe quarterly period ended March 31, 2007, its Annual Report onForm 10-K for the year ended December 31, 2006 and in Pharmion'sother filings with the U.S. Securities and Exchange Commission.Forward-looki...Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
...risks that the Chemical, Manufacturing andControls section of Discovery Labs New Drug Application will notsatisfy the FDA, risks relating to the ability of Discovery Labs orDiscovery Labs third party manufacturers and development partnersto manufacture or provide Discovery Labs with adequate supplies ofdrug ...Medicure's MEND-CABG Trial Results Published in Peer Reviewed Journal
...and its business can be foundin the "Risk Factors" section of its Form 20F for the year endedMay 31, 2006. For more information, please contact: Derek Reimer Adam Peeler Chief Financial Officer Manager of Investor & PublicRelations Tel. 888-435-2220 Fax 204-488-9823 E-mail: <a target="_blank" h...Introgen's Advexin Demonstrates Clinical Benefit in Inherited Cancer
...Spotlighton Clinical Response editorial highlights section of the currentissue of Molecular Cancer Therapeutics, a journal of the AmericanAssociation for Cancer Research. ADVEXIN treatment of a tumor in an LFS patient led toimprovement of tumor-related symptoms and resulted in a completeresponse as determ...Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
...f theconference call, go to the Investor Relations section of theCompany's website at <a target="_blank" href="http://www.iomai.com/">http://www.iomai.com . Please connectto the web site at least 15 minutes prior to the call to allow forany software download that may be necessary. The webcast is als......king statements arediscussed in the "Risk Factors" section and other sections ofKing's Form 10-K for the year ended December 31, 2006 and Form 10-Qfor the quarter ended March 31, 2007, and Palatin's Form 10-K forthe year ended June 30, 2006 and Form 10-Q for the quarters endedSeptember 30, 2006, December 31,...Antipsychotic Iloperidone Results Show Favorable Akathisia Profile
...er factors that are described in the"Risk Factors" section (Item 1A) of Vanda's annual report on Form10-K for the year ended December 31, 2006 (File No. 000-51863). Noforward-looking statements can be guaranteed and actual results maydiffer materially from such statements. The information in thisrelease is p...XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
...entation can beaccessed via the investor relations section of the Company'swebsite at <a target="_blank" ...dicted and whichare included in the "Risk Factors" section of our most recentquarterly report on Form 10-Q for the quarter ended March 31, 2007.This quarterly ...PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
... copies of which may be obtained atthe "Investors" section on PDL's website at <a target="_blank"href="http://www.pdl.com/">www.pdl.com . All forward-lookingstatements in this press release are qualified in their entirety bythis cautionary statement. NOTE: PDL BioPharma and the PDL BioPharma logo ar...Other ContentscarnivorecarnivorefixationfixationfixationfixationfixationfixationfixationfixationcarboncarboncarboncarboncarboncarboncarboncarriercarriercarriercarriercarriercarriercarriercarriercarriercartilagecartilagecartilagecartilagecartilagecartilagecartilagedivisiondivisiondivisiondivisiondivisiondivisiondivisionanabolismanabolismnucleusnucleusnucleusnucleusnucleusnucleusnucleusnucleusnucleusOther TagscoastparkparkparkparkparkeacheacheacheacheachboxespregnanciesOther Tagscorticosteroid 2systemic 2systemic 3systemic 4systemic 5systemic 6predispose 2predispose 3predispose 4coli 2coli 3coli 4coli 5investigating 2investigating 3investigating 4investigating 5investigating 6investigating 7investigating 8evade 2evade 3
(Date:7/24/2008)...lvania State University College of Medicine, Hersh... of imiquimod, a clinically important immune respo...ctivity, is dependent on the Opioid Growth Factor ...is discovery, reported in the August 08 issue of ...nsights into a widely used drug that may lead to d...
(Date:7/24/2008)...uly 24, 2008) A multi-institutional team of resea...Minnesota Medical School, have developed a powerfu...st method will allow researchers to generate synth...quences for inactivation or repair. , The potenti... director of the Arnold and Mabel Beckman Center f...
(Date:7/24/2008)...008. A fire is currently burning through a study a...r about 2 years ago. Managers used data and analys...) study in the planning, analysis, and implementat... is now active., The Gotchen LSR, lies on the ea...overs about 15,000 acres of the Mount Adams Ranger...
(Date:7/23/2008)...08 One of the reasons people on low-carbohydrate ...take of fructose, a type of sugar that can be made...at UT Southwestern Medical Center. , Dr. Eliza...ion and lead author of a study appearing in a curr...team,s findings suggest that the right type of car...
Breaking Biology News(10 mins):Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2Consortium develops new method to manipulate genetic material 2Landscape study may offer solutions for fire managers 2Limiting fructose may boost weight loss, UT Southwestern researcher reports 2Limiting fructose may boost weight loss, UT Southwestern researcher reports 3Statement by Oscar S Wyatt Jr 1322 1Statement by Mike Leavitt Secretary of Health and Human Services on the United States China Bilateral Meetings on Food and Drug Safety 1318 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 2Monsanto Company Signs Share Subscription Agreement With Devgen 594 3Womens Folic Acid Levels Improving 1312 1Womens Folic Acid Levels Improving 1312 2Womens Folic Acid Levels Improving 1312 3Womens Folic Acid Levels Improving 1312 4(Date:7/25/2008)... to benefit ALS Therapy Alliance to be presented a...ht, WOONSOCKET, R.I., July 25 /PRNewswire/ -- CVS...ised a record-breaking $4.4 million in just 21 day... for ALS research. This is,the seventh year of the...sed more than $15 million for ALS research. This y...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... New program delivers immediate co...[24-hour telephone access to language interpreters...g multilingual solutions. , ...LLE® http://www.lle-inc.com/index.html [(Lan...ider of interpretation, translation, and language ...
(Date:7/25/2008)... Whether you are an Olympian, Prof..., there are Five Things You Need to Know about Hyd....C. Spine and Sports Center , ...-- America,s premier athletes are heading to Beiji...ng and sacrifice in the hopes of capturing an Olym...
Breaking Medicine News(10 mins):Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:People With GERD More Likely to Develop Asthma 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5[0] CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign[0] People With GERD More Likely to Develop Asthma[0] LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program[0] Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know
| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |